Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss [Seeking Alpha]
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
3.48K Follower s Follow Summary Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and systemic absorption issues, unlike seralutinib, which targets key disease pathways effectively. Tyvaso DPI's success in PH-ILD highlights the unmet need, with Gossamer planning a Phase 3 trial for seralutinib in mid-2025. Seralutinib's potential in PH-ILD and PAH, combined with its safety profile, positions it as a strong contender in the biopharmaceutical market. BlackJack3D Gossamer Bio ( NASDAQ: GOSS ) is a clinical-stage biopharmaceutical company with a pipeline of one drug: Seralutinib . Seralutinib is focused on treating pulmonary arterial hypertension ("PAH") and pulmonary hypertension with interstitial lung disease ("PH-ILD"). The company has a history of disappointing investors, typical in biotech, as 90% of drugs fail clinical tri
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire
- Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Several Insiders Invested In Gossamer Bio Flagging Positive News [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
GOSS
Earnings
- 8/12/24 - Miss
GOSS
Sec Filings
- 11/7/24 - Form 8-K
- 11/7/24 - Form 10-Q
- 9/13/24 - Form 8-K
- GOSS's page on the SEC website